FDA approves AstraZeneca’s Saphnelo Pen for self-administered lupus treatment
The U.S. Food and Drug Administration has approved AstraZeneca’s (NASDAQ:AZN) Saphnelo (anifrolumab) for self-administration via a once-weekly autoinjector, the Saphnelo Pen.








-640x360.webp&w=3840&q=75)

_1387413_640x360_2497849411974-640x360.webp&w=3840&q=75)
